Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

How does padcev work?

See the DrugPatentWatch profile for padcev

How does Padcev (enfortumab vedotin-ejfv) work to treat cancer?

Padcev is an antibody-drug conjugate (ADC). It targets Nectin-4, a protein found at higher levels on many tumor cells, and delivers a chemotherapy-like payload directly into those cells.

The drug works in two coordinated steps:
- Targeting: The antibody portion binds to Nectin-4 on the cancer cell surface.
- Killing the cell: After binding, the ADC is brought into the cell. The payload then disrupts the cancer cell’s ability to survive and multiply.

This “seek-and-destroy” design is intended to focus the toxic payload on Nectin-4–expressing tumors rather than relying on broadly acting chemotherapy.

What does “antibody-drug conjugate” mean in plain terms?

An antibody-drug conjugate is made of:
- An antibody that recognizes a specific target on cells (here, Nectin-4),
- A linker that keeps the payload attached until the drug is inside the tumor cell,
- A cytotoxic payload that kills cells once released.

Because the payload is carried by the antibody, the drug can combine targeted binding with a cytotoxic effect.

Why target Nectin-4—what role does it play?

Nectin-4 is the binding target for Padcev. Tumors with higher Nectin-4 expression are the main cells Padcev is designed to recognize, which helps explain why patient selection and tumor characteristics can matter for benefit.

What happens after Padcev binds—does it work only on the tumor cell?

The primary mechanism is direct action on Nectin-4–expressing cancer cells after internalization and payload release. As with other ADCs, the overall tumor response is driven by how effectively the drug reaches and binds the target and how much payload is released inside cancer cells.

Are there common reasons Padcev might not work as well?

Mechanisms that can reduce effectiveness with ADCs include:
- Low or absent Nectin-4 expression on tumor cells,
- Reduced internalization of the ADC after binding,
- Changes in how tumor cells handle or respond to the released payload.

If you tell me what cancer type you mean (Padcev is used in specific settings), I can tailor the explanation to that context.



Other Questions About Padcev :

Is Padcev used for bladder cancer? Is Padcev used for bladder cancer? Is Padcev used for bladder cancer? What are the side effects of padcev? Is Padcev used for bladder cancer? Is Padcev used for bladder cancer? Is Padcev used for bladder cancer?